Viatris Inc. (VTRS)
Are Investors Undervaluing Viatris (VTRS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Viatris (VTRS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.
Here's Why Viatris (VTRS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)
Viatris (VTRS) is upgraded to Strong Buy, underpinned by robust pipeline catalysts and a credible long-term growth framework. Viatris targets a five-year sales CAGR midpoint of 3.5%, exceeding consensus, with $450–550 million annual new product contributions and upside from branded assets. Key assets such as Selatogrel and Cenerimod, alongside upcoming launches (e.g., meloxicam), support reacceleration in growth and margin expansion.
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating
Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now.
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
VTRS beats Q1 estimates as revenues climb 8% on strong Greater China and brands sales, while management reaffirms 2026 guidance.
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
